Active	Status	Sponsor type	Region	Phase	Filter
7 Active 15 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Janku, Filip
NCT04167137: Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants Oct 2021 - Dec 2021 : Data from trial in combination with Tecentriq for solid tumors and lymphoma Presentation of data for the treatment of solid tumors and lymphoma at AACR 2021 Apr 2021 - Apr 2021: Presentation of data for the treatment of solid tumors and lymphoma at AACR 2021 Initiation of study arm of P1 trial in combination with Tecentriq for solid tumors and lymphoma Dec 2020 - Dec 2020: Initiation of study arm of P1 trial in combination with Tecentriq for solid tumors and lymphoma Data from trial for solid tumors and lymphoma Dec 2020 - Dec 2020: Data from trial for solid tumors and lymphoma More	Terminated	1	32	US	SYNB1891, Atezolizumab	Synlogic, IQVIA Biotech	Metastatic Solid Neoplasm, Lymphoma	12/21	12/21
NCT04096638: Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors Data from trial in combination with Tecentriq for solid tumors Jul 2021 - Jul 2021: Data from trial in combination with Tecentriq for solid tumors	Completed	1	61	US	SB 11285, Atezolizumab, Tecentriq	invoX Pharma Limited	Melanoma, Head and Neck Squamous Cell Carcinoma, Solid Tumor	07/24	07/24